Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.33 |
| ▸ | CD81 | P60033 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521493 | 0.95 | EP300 (0.43) | EP300CES2CD81TBXAS1EPHX2 | |
| SCHEMBL22972967 | 0.93 | EP300 (0.46) | EP300CES2TBXAS1EPHX2 | |
| SCHEMBL15544384 | 0.93 | EP300 (0.44) | EP300CES2TSHRGRIK1ALDH1A1 | |
| SCHEMBL522917 | 0.89 | ALDH1A1 (0.42) | EP300CES2TSHRCD81ALDH1A1 | |
| SCHEMBL303833 | 0.89 | CD81 (0.35) | EP300CES2GRIK1CD81ALDH1A1 | |
| SCHEMBL3427734 | 0.89 | ALDH1A1 (0.42) | EP300CES2TSHRCD81ALDH1A1 | |
| SCHEMBL871680 | 0.87 | EP300 (0.47) | EP300CES2TSHRALDH1A1HCAR2 | |
| SCHEMBL721144 | 0.87 | CD81 (0.34) | EP300TSHRGRIK1CD81ALDH1A1 | |
| SCHEMBL22972971 | 0.86 | EP300 (0.50) | EP300CES2TSHRALDH1A1EPHX2 | |
| SCHEMBL3120499 | 0.85 | EP300 (0.40) | EP300CES2TSHRCD81ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321602-A1 | SULFUR FREE POLY ALKYL(METH)ACRYLATE COPOLYMERS AS VISCOSITY INDEX IMPROVERS IN LUBRICANTS | Evonik Operations GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-11795413-B2 | Viscosity index improver and lubricant compositions thereof | EVONIK OPERATIONS GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| EP-4060009-B1 | VISCOSITY INDEX IMPROVER AND LUBRICANT COMPOSITIONS THEREOF | EVONIK OPERATIONS GMBH (DE) | 2023-05-03 | — | — | EP | disclosed |
| US-20220306962-A1 | VISCOSITY INDEX IMPROVER AND LUBRICANT COMPOSITIONS THEREOF | EVONIK OPERATIONS GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3778839-B1 | VISCOSITY INDEX IMPROVER WITH IMPROVED SHEAR-RESISTANCE | EVONIK OPERATIONS GMBH (DE) | 2021-08-04 | — | — | EP | disclosed |
| EP-3778839-A1 | VISCOSITY INDEX IMPROVER WITH IMPROVED SHEAR-RESISTANCE | Evonik Operations GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-9186441-B2 | Surface treating agent, filtering material for filter, and blood treatment filter | TERUMO KABUSHIKI KAISHA (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20120024779-A1 | SURFACE TREATING AGENT, FILTERING MATERIAL FOR FILTER, AND BLOOD TREATMENT FILTER | TERUMO KABUSHIKI KAISHA (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7696257-B2 | Oxime ester compound and photopolymerization initiator containing such compound | ADEKA CORPORATION (JP) | 2010-04-13 | — | — | US | disclosed |
| US-20070270522-A1 | Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound | ADEKA CORPORATION (JP) | 2007-11-22 | — | — | US | disclosed |
| US-3960762-A | Production of absorbents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270522-A1 | Oxime Ester Compound and Photopolymerization Initiator Containing Such Compound | CBR3, CBR1, SCLY | EP300 1203/4885CES2 126/4885TSHR 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.